Volume 17, Issue 4 (Jul-Aug 2023)                   mljgoums 2023, 17(4): 20-23 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Sabouri S, Hamidi Alamdari D, Salaramoli S, Hashemy S I. Prooxidant-antioxidant balance in relapsing-remitting multiple sclerosis patients. mljgoums 2023; 17 (4) :20-23
URL: http://mlj.goums.ac.ir/article-1-1453-en.html
1- Department of Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
2- Department of Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran , HamidiAD@mums.ac.ir
3- Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
Abstract:   (307 Views)
Samaneh Sabouri , Darioush Hamidi Alamdari , Sanaz Salaramoli , Seyyed Isaac Hashemy
Background: Multiple sclerosis (MS) is a demyelination disorder of the central nervous system (CNS), which is believed to be associated with oxidative stress. Therefore, researchers try to find reliable biomarkers to monitor the disease and predict its prognosis. Cholesterol and lipids in the myelin sheath are vital for nerve cells. Serum low-density lipoprotein (LDL) is susceptible to lipid peroxidation induced by oxidative stress. This study aimed to evaluate oxidative stress markers in the serum of patients with relapsing-remitting MS (RRMS) and examine their correlation with lipid markers.
Methods: A total of 18 MS patients (14 women and 4 men) and 18 healthy subjects (matched by age and sex) were enrolled in this cross-sectional study. The serum samples were collected in both relapsing and remitting phases. The prooxidant-antioxidant balance (PAB), malondialdehyde (MDA), and oxidized LDL (oxLDL) were measured as markers of oxidative stress.
Results: The mean age of participants was 29.21 (22-42) years. In the comparison between the patient and control groups, the most differences were increased levels of PAB in the patient group (P < 0.05), no difference between relapsing and remitting phases (P = 0.995), increased MDA levels in the relapsing phase (P = 0.013)––but no change in the remitting phase (P = 0.068), no difference in LDL and oxLDL levels in the patient group (P > 0.05), and MDA, LDL, and oxLDL levels did not have any significant correlation with PAB (P > 0.05).
Conclusion: High levels of oxidative stress markers were present in both phases of the disease. Lipid peroxidation markers (such as MDA) increased in the acute phase, but oxLDL did not change. Also, there was no significant correlation between oxidative stress and cholesterol markers.
Full-Text [PDF 484 kb]   (66 Downloads) |   |   Full-Text (HTML)  (74 Views)  
Research Article: Original Paper | Subject: Biochemistry
Received: 2021/10/23 | Accepted: 2022/10/10 | Published: 2023/10/2 | ePublished: 2023/10/2

1. Yazdi A, Ghasemi‐Kasman M, Javan M. Possible regenerative effects of fingolimod (FTY720) in multiple sclerosis disease: An overview on remyelination process. J Neurosci Res. 2020;98(3):524-36. [View at Publisher] [DOI] [PMID] [Google Scholar]
2. Van Doorn RP. Harmony of Citizens is the Wall of Cities: orchestrating the neurovascular unit. VU University;2013. [View at Publisher] [DOI] [Google Scholar]
3. Barth H, Klein K, Börtlein A, Guseo A, Berg P, Wiethölter H, et al. Analysis of immunoregulatory T-helper cell subsets in patients with multiple sclerosis: relapsing-progressive course correlates with enhanced TH1, relapsing-remitting course with enhanced TH0 reactivity. J Neuroimmunol. 2002;133(1-2):175-83. [View at Publisher] [DOI] [PMID] [Google Scholar]
4. Patel J, Balabanov R. Molecular mechanisms of oligodendrocyte injury in multiple sclerosis and experimental autoimmune encephalomyelitis. Int J Mol Sci. 2012;13(8):10647-59. [View at Publisher] [DOI] [PMID] [Google Scholar]
5. Yang L, Tan D, Piao H. Myelin basic protein citrullination in multiple sclerosis: a potential therapeutic target for the pathology. Neurochem Res. 2016;41(8):1845-56. [View at Publisher] [DOI] [PMID] [Google Scholar]
6. Egawa J, Pearn ML, Lemkuil BP, Patel PM, Head BP. Membrane lipid rafts and neurobiology: age‐related changes in membrane lipids and loss of neuronal function. The J Physiol. 2016;594(16):4565-79. [View at Publisher] [DOI] [PMID] [Google Scholar]
7. Orth M, Bellosta S. Cholesterol: its regulation and role in central nervous system disorders. Cholesterol. 2012;2012:292598. [View at Publisher] [DOI] [PMID] [Google Scholar]
8. Robert J, Button EB, Yuen B, Gilmour M, Kang K, Bahrabadi A, et al. Clearance of beta-amyloid is facilitated by apolipoprotein E and circulating high-density lipoproteins in bioengineered human vessels. Elife. 2017;6:e29595. [View at Publisher] [DOI] [PMID] [Google Scholar]
9. Zhao Y, Li D, Zhao J, Song J, Zhao Y. The role of the low-density lipoprotein receptor-related protein 1 (LRP-1) in regulating blood-brain barrier integrity. Rev Neurosci. 2016;27(6):623-34. [View at Publisher] [DOI] [PMID] [Google Scholar]
10. Mezger M, Göbel K, Kraft P, Meuth S, Kleinschnitz C, Langer H. Platelets and vascular inflammation of the brain. Hämostaseologie. 2015;35(3):244-51. [View at Publisher] [DOI] [PMID] [Google Scholar]
11. Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron. 2008;57(2):178-201. [View at Publisher] [DOI] [PMID] [Google Scholar]
12. Liu Z, Zhou T, Ziegler AC, Dimitrion P, Zuo L. Oxidative stress in neurodegenerative diseases: from molecular mechanisms to clinical applications. Oxid Med Cell Longev. 2017;2017:2525967. [View at Publisher] [DOI] [PMID] [Google Scholar]
13. Acar A, Cevik MU, Evliyaoglu O, Uzar E, Tamam Y, Arıkanoglu A, et al. Evaluation of serum oxidant/antioxidant balance in multiple sclerosis. Acta Neurol Belg. 2012;112(3):275-80. [View at Publisher] [DOI] [PMID] [Google Scholar]
14. Ghafourifar P, Mousavizadeh K, Parihar MS, Nazarewicz RR, Parihar A, Zenebe WJ. Mitochondria in multiple sclerosis. Front Biosci. 2008;13(8):3116-26. [View at Publisher] [DOI] [PMID] [Google Scholar]
15. Campbell GR, Ziabreva I, Reeve AK, Krishnan KJ, Reynolds R, Howell O, et al. Mitochondrial DNA deletions and neurodegeneration in multiple sclerosis. Ann Neurol. 2011;69(3):481-92. [View at Publisher] [DOI] [PMID] [Google Scholar]
16. Rahal A, Kumar A, Singh V, Yadav B, Tiwari R, Chakraborty S, et al. Oxidative stress, prooxidants, and antioxidants: the interplay. BioMed Res Int. 2014;2014:761264. [View at Publisher] [DOI] [PMID] [Google Scholar]
17. Ferretti G, Bacchetti T. Peroxidation of lipoproteins in multiple sclerosis. J Neurol Sci. 2011;311(1-2):92-7. [View at Publisher] [DOI] [PMID] [Google Scholar]
18. Azbill RD, Mu X, Bruce-Keller AJ, Mattson MP, Springer JE. Impaired mitochondrial function, oxidative stress and altered antioxidant enzyme activities following traumatic spinal cord injury. Brain Res. 1997;765(2):283-90. [View at Publisher] [DOI] [PMID] [Google Scholar]
19. Uttara B, Singh AV, Zamboni P, Mahajan RT. Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options. Curr Neuropharmacol. 2009;7(1):65-74. [View at Publisher] [DOI] [PMID] [Google Scholar]
20. Inojosa H, Proschmann U, Akgün K, Ziemssen T. A focus on secondary progressive multiple sclerosis (SPMS): challenges in diagnosis and definition. J Neurol. 2021;268(4):1210-21. [View at Publisher] [DOI] [PMID] [Google Scholar]
21. Adamczyk B, Adamczyk-Sowa M. New insights into the role of oxidative stress mechanisms in the pathophysiology and treatment of multiple sclerosis. Oxid Med Cell Longev. 2016;2016:1973834. [View at Publisher] [DOI] [PMID] [Google Scholar]
22. Gilgun-Sherki Y, Melamed E, Offen D. The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy. J Neurol. 2004;251(3):261-8. [View at Publisher] [DOI] [PMID] [Google Scholar]
23. Karlík M, Valkovič P, Hančinová V, Krížová L, Tóthová Ľ, Celec P. Markers of oxidative stress in plasma and saliva in patients with multiple sclerosis. Clin Biochem. 2015;48(1-2):24-8. [View at Publisher] [DOI] [PMID] [Google Scholar]
24. Sadowska-Bartosz I, Adamczyk-Sowa M, Galiniak S, Mucha S, Pierzchala K, Bartosz G. Oxidative modification of serum proteins in multiple sclerosis. Neurochem Int. 2013;63(5):507-16. [View at Publisher] [DOI] [PMID] [Google Scholar]
25. Olsson T, Zhi WW, Höjeberg B, Kostulas V, Jiang Y, Anderson G, et al. Autoreactive T lymphocytes in multiple sclerosis determined by antigen-induced secretion of interferon-gamma. J Clin Invest. 1990;86(3):981-5. [View at Publisher] [DOI] [PMID] [Google Scholar]
26. Höftberger R, Lassmann H. Inflammatory demyelinating diseases of the central nervous system. Handb Clin Neurol. 2017;145:263-83. [View at Publisher] [DOI] [PMID] [Google Scholar]
27. Yu Y, Yu Z, Xie M, Wang W, Luo X. Hv1 proton channel facilitates production of ROS and pro-inflammatory cytokines in microglia and enhances oligodendrocyte progenitor cells damage from oxygen-glucose deprivation in vitro. Biochem Biophys Res Commun. 2018;498(1):1-8. https://doi.org/10.1016/j.bbrc.2017.06.197 [View at Publisher] [DOI] [PMID] [Google Scholar]
28. Sadeghian M, Mastrolia V, Haddad AR, Mosley A, Mullali G, Schiza D, et al. Mitochondrial dysfunction is an important cause of neurological deficits in an inflammatory model of multiple sclerosis. Sci Rep. 2016;6(1):33249. [View at Publisher] [DOI] [PMID] [Google Scholar]
29. Golpich M, Amini E, Mohamed Z, Azman Ali R, Mohamed Ibrahim N, Ahmadiani A. Mitochondrial dysfunction and biogenesis in neurodegenerative diseases: pathogenesis and treatment. CNS Neurosci Ther. 2017;23(1):5-22. [View at Publisher] [DOI] [PMID] [Google Scholar]
30. Fetisova E, Chernyak B, Korshunova G, Muntyan M, Skulachev V. Mitochondria-targeted antioxidants as a prospective therapeutic strategy for multiple sclerosis. Curr Med Chem. 2017;24(19):2086-114. [View at Publisher] [DOI] [PMID] [Google Scholar]
31. Avval FZ, Mahmoudi N, Tirkani AN, Jarahi L, Alamdari DH, Sadjadi SA. Determining Pro-oxidant antioxidant balance (PAB) and total antioxidant capacity (tac) in patients with schizophrenia. Iran J Psychiatry. 2018;13(3):222-6. [View at Publisher] [DOI] [PMID] [Google Scholar]
32. Redza-Dutordoir M, Averill-Bates DA. Activation of apoptosis signalling pathways by reactive oxygen species. Biochim Biophys Acta (BBA). 2016;1863(12):2977-92. [View at Publisher] [DOI] [PMID] [Google Scholar]
33. Chen L, Deng H, Cui H, Fang J, Zuo Z, Deng J, et al. Inflammatory responses and inflammation-associated diseases in organs. Oncotarget. 2017;9(6):7204-18. [View at Publisher] [DOI] [PMID] [Google Scholar]
34. Carlström KE, Ewing E, Granqvist M, Gyllenberg A, Aeinehband S, Enoksson SL, et al. Therapeutic efficacy of dimethyl fumarate in relapsing-remitting multiple sclerosis associates with ROS pathway in monocytes. Nat Commun. 2019;10(1):3081. [View at Publisher] [DOI] [PMID] [Google Scholar]
35. Correale J, Marrodan M, Ysrraelit MC. Mechanisms of neurodegeneration and axonal dysfunction in progressive multiple sclerosis. Biomedicines. 2019;7(1):14. [View at Publisher] [DOI] [PMID] [Google Scholar]
36. Adamczyk B, Wawrzyniak S, Kasperczyk S, Adamczyk-Sowa M. The evaluation of oxidative stress parameters in serum patients with relapsing-remitting multiple sclerosis treated with II-line immunomodulatory therapy. Oxid Med Cell Longev. 2017;2017:9625806. [View at Publisher] [DOI] [PMID] [Google Scholar]
37. Acar A, Ugur Cevik M, Evliyaoglu O, Uzar E, Tamam Y, Arıkanoglu A, et al. Evaluation of serum oxidant/antioxidant balance in multiple sclerosis. Acta Neurol Belg. 2012;112(3):275-80. [View at Publisher] [DOI] [PMID] [Google Scholar]
38. Van Horssen J, Schreibelt G, Drexhage J, Hazes T, Dijkstra C, Van der Valk P, et al. Severe oxidative damage in multiple sclerosis lesions coincides with enhanced antioxidant enzyme expression. Free Radic Biol Med. 2008;45(12):1729-37. [View at Publisher] [DOI] [PMID] [Google Scholar]
39. Hendriks JJ, Teunissen CE, de Vries HE, Dijkstra CD. Macrophages and neurodegeneration. Brain Res Rev. 2005;48(2):185-95. [View at Publisher] [DOI] [PMID] [Google Scholar]
40. Gielen A, Khademi M, Muhallab S, Olsson T, Piehl F. Increased Brain‐Derived Neurotrophic Factor Expression in White Blood Cells of Relapsing-Remitting Multiple Sclerosis Patients. Scand J Immunol. 2003;57(5):493-7. [View at Publisher] [DOI] [PMID] [Google Scholar]
41. Stephenson J, Nutma E, van der Valk P, Amor S. Inflammation in CNS neurodegenerative diseases. Immunology. 2018;154(2):204-19. [View at Publisher] [DOI] [PMID] [Google Scholar]
42. Milstein JL, Barbour CR, Jackson K, Kosa P, Bielekova B. Intrathecal, not systemic inflammation is correlated with Multiple Sclerosis severity, especially in Progressive Multiple Sclerosis. Front Neurol. 2019;10:1232. [View at Publisher] [DOI] [PMID] [Google Scholar]
43. Breedveld A, Groot Kormelink T, van Egmond M, de Jong EC. Granulocytes as modulators of dendritic cell function. J Leukoc Biol. 2017;102(4):1003-16. [View at Publisher] [DOI] [PMID] [Google Scholar]
44. Woodberry T, Bouffler SE, Wilson AS, Buckland RL, Brüstle A. The emerging role of neutrophil granulocytes in multiple sclerosis. J Clin Med. 2018;7(12):511. [View at Publisher] [DOI] [PMID] [Google Scholar]
45. Hasan R, Rink L, Haase H. Chelation of free Zn 2+ impairs chemotaxis, phagocytosis, oxidative burst, degranulation, and cytokine production by neutrophil granulocytes. Biol Trace Elem Res. 2016;171(1):79-88. [View at Publisher] [DOI] [PMID] [Google Scholar]
46. Vasileiadis GK, Dardiotis E, Mavropoulos A, Tsouris Z, Tsimourtou V, Bogdanos DP, et al. Regulatory B and T lymphocytes in multiple sclerosis: friends or foes? Auto Immun Highlights. 2018;9(1):9. [View at Publisher] [DOI] [PMID] [Google Scholar]
47. Siwicka-Gieroba D, Malodobry K, Biernawska J, Robba C, Bohatyrewicz R, Rola R, et al. The Neutrophil/Lymphocyte Count Ratio Predicts Mortality in Severe Traumatic Brain Injury Patients. J Clin Med. 2019;8(9):1453. [View at Publisher] [DOI] [PMID] [Google Scholar]
48. Mariani E, Polidori MC, Cherubini A, Mecocci P. Oxidative stress in brain aging, neurodegenerative and vascular diseases: An overview. J Chromatogr B Analyt Technol Biomed Life Sci. B. 2005;827(1):65-75. [View at Publisher] [DOI] [PMID] [Google Scholar]
49. Besler HT, Çomogˇlu S. Lipoprotein oxidation, plasma total antioxidant capacity and homocysteine level in patients with multiple sclerosis. Nutr Neurosci. 2003;6(3):189-96. [View at Publisher] [DOI] [PMID] [Google Scholar]

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2007 All Rights Reserved | Medical Laboratory Journal

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.